Dr. Kostas Stamatopoulos
This video provides an overview of the 2024 ASH Conference updates, featuring presentations by Prof. Kostas Stamatopoulos on advancements in hematology, including precision medicine, immunobiology, and clinical studies.
01:01Â - Disclosures and selected advances in hematology.
02:31Â - Studies on immunogenetics, epigenomics, and bioenergetics.
04:53Â - Research on cell adaptation and monoclonal antibodies.
06:19Â - PD-1 expression and resistance to BTK inhibitor therapy.
08:35Â - Tumor microenvironment and T-cell responses to Venetoclax.
10:01Â - Clinical trial findings on T-cell recovery and exhaustion.
Dr. Shankara Paneesha
This video discusses various clinical trials and studies on BTK inhibitors, BCL-2 inhibitors, and other treatments for CLL, highlighting their efficacy, progression-free survival rates, and impact on patients' quality of life presented by Dr. Shankara Paneesha.
00:33 -Â Overview of BTK inhibitors and BCL-2 inhibitors.
01:42 -Â Presentation of quality of life data from Ash 2024.
03:42 -Â Kaplan marker and progression-free survival.
06:17 -Â Benefits of second-generation BTK inhibitors.
09:30 -Â Outcomes with continuous BTK inhibitor treatment.
15:29 -Â Pivotal study on third-generation BCL-2 inhibitors.
20:44 -Â High-risk patient outcomes.
25:14 -Â Take-home message on treatment direction.
Panel Discussion
The discussion primarily focuses on the evolving strategies and challenges in first-line treatment, emphasizing the importance of balancing efficacy, safety, and patient preferences in clinical trials and treatment plans.
00:00 -Â Characteristics of a Good First-Line Treatment
01:13 -Â Challenges in Achieving a Cure
02:33 -Â Financial Toxicity and Treatment Goals
03:46 -Â Clinical Trials and Standard Practice
06:10 -Â Impact of Covid on Treatment Outcomes
08:21 -Â Role of Anti-CD20 in Treatment
09:55 -Â Future of CLL Treatment